对巴龙霉素治疗内脏利什曼病（黑热病）的兴趣。
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).
机构信息
Wiwanitkit House, Bang Khae, Bangkok, Thailand.
出版信息
Ther Clin Risk Manag. 2012;8:323-8. doi: 10.2147/TCRM.S30139. Epub 2012 Jun 22.
Abstract
Leishmaniasis is an important vector-borne disease, and it is classified as one of the most important tropical fly-borne infections. This disease can cause two types of clinical manifestations: cutaneous forms and visceral forms. Visceral leishmaniasis, which is also called kala-azar, is a very serious infection that can be fatal. The management of visceral leishmaniasis requires informed diagnostic and therapeutic approaches. Continuous research and development regarding the treatment of visceral leishmaniasis had led to many improvements. Paromomycin is a relatively new antibiotic drug that has been used for the treatment of visceral leishmaniasis for several years. This article reviews and discusses the use of paromomycin for visceral leishmaniasis therapy.
摘要
利什曼病是一种重要的经媒介传播的疾病，被归类为最重要的热带虫媒传染病之一。这种疾病可引起两种类型的临床表现：皮肤型和内脏型。内脏利什曼病，也称为黑热病，是一种非常严重的感染，可能致命。内脏利什曼病的管理需要明智的诊断和治疗方法。对内脏利什曼病治疗的持续研究和开发带来了许多改进。巴龙霉素是一种相对较新的抗生素药物，已用于治疗内脏利什曼病数年。本文综述和讨论了巴龙霉素治疗内脏利什曼病的应用。
相似文献
1
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).
Ther Clin Risk Manag. 2012;8:323-8. doi: 10.2147/TCRM.S30139. Epub 2012 Jun 22.
2
Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
J Clin Microbiol. 2012 Apr;50(4):1478-9. doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.
3
Efficacy and Safety of Paromomycin for Visceral Leishmaniasis: A Systematic Review.
J Trop Med. 2021 Jul 24;2021:8629039. doi: 10.1155/2021/8629039. eCollection 2021.
4
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Infect Dis Poverty. 2018 Aug 13;7(1):80. doi: 10.1186/s40249-018-0461-0.
5
Clinical and Hematological Features of Visceral Leishmaniasis at Mymensingh Medical College Hospital.
Mymensingh Med J. 2020 Oct;29(4):879-886.
6
Renal involvement in leishmaniasis: a review of the literature.
NDT Plus. 2011 Jun;4(3):147-52. doi: 10.1093/ndtplus/sfr008. Epub 2011 Mar 21.
7
Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Trop Med Int Health. 2012 Nov;17(11):1345-8. doi: 10.1111/j.1365-3156.2012.03067.x. Epub 2012 Aug 12.
8
Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report.
Rev Soc Bras Med Trop. 2018 Jan-Feb;51(1):105-107. doi: 10.1590/0037-8682-0487-2016.
9
Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches.
Int J Infect Dis. 2000;4(3):158-77. doi: 10.1016/s1201-9712(00)90078-x.
10
Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):615-6. doi: 10.1016/0035-9203(92)90150-b.
引用本文的文献
1
Concomitant use of anti-leishmanial therapy and antibacterial prophylaxis reduces plasma LPS levels and improves several aspects of experimental Leishmania infantum infection in golden hamsters.
Mem Inst Oswaldo Cruz. 2025 Sep 8;120:e240266. doi: 10.1590/0074-02760240266. eCollection 2025.
2
Mechanism of read-through enhancement by aminoglycosides and mefloquine.
Proc Natl Acad Sci U S A. 2025 Apr 29;122(17):e2420261122. doi: 10.1073/pnas.2420261122. Epub 2025 Apr 24.
3
Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.
PLoS Negl Trop Dis. 2025 Jan 3;19(1):e0012735. doi: 10.1371/journal.pntd.0012735. eCollection 2025 Jan.
4
N-methyltubercidin gives sterile cure in a cutaneous mouse model.
Parasitology. 2024 Apr;151(5):506-513. doi: 10.1017/S0031182024000362. Epub 2024 Mar 27.
5
Genomic Insight of Leishmania Parasite: In-Depth Review of Drug Resistance Mechanisms and Genetic Mutations.
ACS Omega. 2024 Mar 8;9(11):12500-12514. doi: 10.1021/acsomega.3c09400. eCollection 2024 Mar 19.
6
Immunotherapy and immunochemotherapy in combating visceral leishmaniasis.
Front Med (Lausanne). 2023 May 17;10:1096458. doi: 10.3389/fmed.2023.1096458. eCollection 2023.
7
Synthesis and physicochemical characterization of Zn-Al layered double hydroxides (LDHs) as a delivery system for amphotericin B: and antileishmanial study.
Heliyon. 2023 Apr 8;9(4):e15308. doi: 10.1016/j.heliyon.2023.e15308. eCollection 2023 Apr.
8
HAS 1: A natural product from soil-isolated species with potent activity against cutaneous leishmaniasis caused by .
Front Pharmacol. 2022 Oct 10;13:1023114. doi: 10.3389/fphar.2022.1023114. eCollection 2022.
9
Experimental Selection of Paromomycin Resistance in Amastigotes Induces Variable Genomic Polymorphisms.
Microorganisms. 2021 Jul 21;9(8):1546. doi: 10.3390/microorganisms9081546.
10
The Search for Putative Hits in Combating Leishmaniasis: The Contributions of Natural Products Over the Last Decade.
Nat Prod Bioprospect. 2021 Oct;11(5):489-544. doi: 10.1007/s13659-021-00311-2. Epub 2021 Jul 14.
本文引用的文献
1
Bioanalytical method development, pharmacokinetics, and toxicity studies of paromomycin and paromomycin loaded in albumin microspheres.
Drug Test Anal. 2013 Jun;5(6):453-60. doi: 10.1002/dta.339. Epub 2012 Mar 22.
2
Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India.
J Clin Microbiol. 2012 Apr;50(4):1478-9. doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.
3
Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India.
J Trop Med. 2011;2011:645203. doi: 10.1155/2011/645203. Epub 2011 Nov 17.
4
Bone marrow leishmaniasis: a review of situation in Thailand.
Asian Pac J Trop Med. 2011 Oct;4(10):757-9. doi: 10.1016/S1995-7645(11)60188-0.
5
Leishmaniasis chemotherapy--challenges and opportunities.
Clin Microbiol Infect. 2011 Oct;17(10):1478-83. doi: 10.1111/j.1469-0691.2011.03630.x.
6
Characterization, thermal stability studies, and analytical method development of Paromomycin for formulation development.
Drug Test Anal. 2011 Jun;3(6):363-72. doi: 10.1002/dta.229. Epub 2010 Dec 29.
7
Leishmaniasis: new insights from an old and neglected disease.
Eur J Clin Microbiol Infect Dis. 2012 Feb;31(2):109-18. doi: 10.1007/s10096-011-1276-0. Epub 2011 May 1.
8
Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine.
Antimicrob Agents Chemother. 2011 Jun;55(6):2916-21. doi: 10.1128/AAC.00812-10. Epub 2011 Apr 4.
9
Visceral leishmaniasis: elimination with existing interventions.
Lancet Infect Dis. 2011 Apr;11(4):322-5. doi: 10.1016/S1473-3099(10)70320-0.
10
Combination therapy for visceral leishmaniasis.
Lancet. 2011 Feb 5;377(9764):443-4. doi: 10.1016/S0140-6736(10)62237-4. Epub 2011 Jan 20.
Zotero 插件